RAP-219, formerly known as JNJ-64300912, is an AMPA receptor negative allosteric modulator which is under development for the treatment of partial epilepsies, bipolar disorders, and neuropathic pain. It is taken orally. The drug acts specifically as a selective negative allosteric modulator of the transmembrane AMPA receptor regulatory protein (TARP) γ-8 and potently and selectively inhibits TARP γ-8-containing AMPA receptors. The time to peak levels of RAP-219 is approximately 4 hours and its elimination half-life is 278 hours. RAP-219 is under development by Rapport Therapeutics. As of May 2026, it is in phase 3 clinical trials for partial epilepsies, phase 2 trials for bipolar disorders, and phase 1 trials for neuropathic pain. The drug is an azabenzimidazole derivative of undisclosed chemical structure.
See also List of investigational bipolar disorder drugs
References